Autonomix Medical (AMIX)
Develops transvascular catheters to sense, target, and ablate peripheral nerves.
Something off on this page? Send us feedback.
Develops a pre-commercial transvascular catheter system intended to sense, map, ablate, and verify peripheral-nerve targets. It plans procedure-based revenue from single-use catheters, a generator, and software, but its proprietary sensing catheter remains a hand-built prototype requiring validation and FDA review.
Develops a transvascular catheter platform intended to find faint peripheral-nerve signals, apply radiofrequency energy to selected nerve tissue, and verify whether signals have been interrupted. Its lead human program targets pancreatic-cancer pain, while a standalone sensing program for renal denervation remains preclinical.
Plans procedure-based revenue from single-use sensing and ablation catheters sold to hospital catheterization laboratories, alongside a generator and software interface. Production is outsourced, and it has no product clearance, commercial sales, or operating revenue.
Depends on engineering and clinical validation of its proprietary devices, FDA review, financing, a single lead-device manufacturer, and eventual reimbursement. The sensing catheter remains a hand-built prototype not cleared for human use.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.5M · Total debt $0 · Total assets $4.0M · Shareholders' equity $3.2M
- Revenue
- $0
- Operating income
- −$2.8M
- Net income
- −$2.7M
No dividends on record.
| Institutions | 3.14% | 17.0K shares | |
|---|---|---|---|
| 15 holders · as of Mar 31, 2026 | |||
| Insiders | 13.88% | 75.4K shares | |
| 4 holders · as of Sep 21, 2026 | |||
| Other | 82.98% | 450.6K shares | |
| remainder | |||
543.0K company shares as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (971.0K in the company's Sep 22, 2026 report, 543.0K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Bradley HauserInsiderofficer: CEO and President | 4.97% | 27,000 | filed Sep 8, 2026 |
Walter V. KlempInsiderdirector | 3.70% | 20,118 | filed Sep 8, 2026 |
Trent N. SmithInsiderofficer: CFO | 2.78% | 15,119 | filed Sep 21, 2026 |
Lori BissonInsiderdirector | 2.42% | 13,119 | filed Sep 8, 2026 |
Geode Capital Management, LLCInstitution | 1.54% | 175,621 | as of Mar 31, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Medtronic
Direct renal-denervation rival with RF catheter and generator.
- Johnson & Johnson
Integrated mapping and ablation platform rival in catheter labs.
- Abbott
EP mapping and RF-ablation system rival in hospital labs.
- Boston Scientific
Large EP ablation rival with a scaled catheter-lab platform.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Autonomix Medical | $4.14 | +2.22% | $2.2M | — | — | — | — |
| Medtronic | $90.85 | −0.98% | $117.44B | 22.6 | 15.1 | 3.1 | +13.7% |
| Johnson & Johnson | $269.34 | −0.05% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Abbott | $104.23 | +1.21% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| Boston Scientific | $45.07 | +3.08% | $64.98B | 17.8 | 13.7 | 3.1 | +7.5% |
| Median | 26.9 | 16.6 | 3.5 | +10.3% |